Hypoxia-targeted Radiotherapy Boost for GBM
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the use of dynamic contrast-enhanced MRI (DSC-MRI) to identify and target hypoxic tumor regions in glioblastoma (GBM). The study is divided into two phases: Phase 1 will focus on biologic validation in newly diagnosed GBM patients, while Phase 2 will assess the clinical implementation of DSC-MRI-guided radiotherapy in recurrent or postoperative GBM patients. The primary endpoints are the validation of DSC-MRI in identifying hypoxic regions and assessing the safety and efficacy of radiation therapy based on these findings.
Who Is on the Research Team?
Jonathan So, MD, PhD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants with postoperative or recurrent GBM will receive DSC-MRI-informed radiotherapy, including a targeted radiation boost to hypoxic subvolumes while maintaining standard dose constraints for organs at risk. Standard-of-care MRI will be performed before and after radiotherapy, with an optional mid-treatment DSC-MRI to assess hypoxia dynamics and support adaptive radiation planning.
Participants with newly diagnosed, resectable GBM will undergo pre-operative DSC-MRI to generate individualized hypoxia maps. Intra-operative neuro-navigation will guide paired sampling of hypoxic and normoxic regions for spatial transcriptomic analysis and IHC to validate DSC-MRI findings.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.